SciBase Holding AB (publ) (SCIB.ST)
SEK 0.37
(-6.03%)
SEK 0.37
(-6.03%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 69.97 Million SEK | 21.19% |
| 2022 | 57.68 Million SEK | 17.75% |
| 2021 | 48.98 Million SEK | 25.88% |
| 2020 | 38.91 Million SEK | -12.15% |
| 2019 | 44.3 Million SEK | -6.77% |
| 2018 | 47.51 Million SEK | 6.02% |
| 2017 | 44.82 Million SEK | -18.72% |
| 2016 | 55.14 Million SEK | 30.9% |
| 2015 | 42.12 Million SEK | 9.95% |
| 2014 | 38.31 Million SEK | 10.11% |
| 2013 | 34.79 Million SEK | 3.77% |
| 2012 | 33.53 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 19.16 Million SEK | 4.3% |
| 2024 Q1 | 18.49 Million SEK | -11.66% |
| 2023 Q2 | 17.14 Million SEK | 19.73% |
| 2023 FY | 69.9 Million SEK | 21.19% |
| 2023 Q4 | 20.93 Million SEK | 18.47% |
| 2023 Q3 | 17.67 Million SEK | 3.08% |
| 2023 Q1 | 14.32 Million SEK | -14.3% |
| 2022 Q1 | 12.37 Million SEK | -25.83% |
| 2022 Q4 | 16.71 Million SEK | 17.19% |
| 2022 FY | 57.68 Million SEK | 17.75% |
| 2022 Q2 | 14.34 Million SEK | 15.91% |
| 2022 Q3 | 14.25 Million SEK | -0.58% |
| 2021 Q1 | 9.46 Million SEK | -9.45% |
| 2021 FY | 48.98 Million SEK | 25.88% |
| 2021 Q4 | 16.68 Million SEK | 59.33% |
| 2021 Q3 | 10.47 Million SEK | -15.4% |
| 2021 Q2 | 12.37 Million SEK | 30.82% |
| 2020 Q1 | 10.21 Million SEK | -11.88% |
| 2020 FY | 38.91 Million SEK | -12.15% |
| 2020 Q4 | 10.44 Million SEK | 22.55% |
| 2020 Q3 | 8.52 Million SEK | -12.37% |
| 2020 Q2 | 9.72 Million SEK | -4.77% |
| 2019 FY | 44.3 Million SEK | -6.77% |
| 2019 Q4 | 11.59 Million SEK | 6.97% |
| 2019 Q3 | 10.83 Million SEK | -7.38% |
| 2019 Q2 | 11.7 Million SEK | 15.04% |
| 2019 Q1 | 10.17 Million SEK | -18.29% |
| 2018 Q2 | 11.15 Million SEK | 6.32% |
| 2018 Q4 | 12.44 Million SEK | -7.32% |
| 2018 Q1 | 10.49 Million SEK | -3.37% |
| 2018 FY | 47.51 Million SEK | 6.02% |
| 2018 Q3 | 13.43 Million SEK | 20.42% |
| 2017 FY | 44.82 Million SEK | -18.72% |
| 2017 Q2 | 12.41 Million SEK | 2.83% |
| 2017 Q4 | 10.85 Million SEK | 14.62% |
| 2017 Q1 | 12.07 Million SEK | -20.14% |
| 2017 Q3 | 9.47 Million SEK | -23.73% |
| 2016 Q1 | 11.88 Million SEK | 4.08% |
| 2016 Q3 | 13.11 Million SEK | -12.77% |
| 2016 Q2 | 15.03 Million SEK | 26.5% |
| 2016 Q4 | 15.12 Million SEK | 15.33% |
| 2016 FY | 55.14 Million SEK | 30.9% |
| 2015 Q3 | 10.46 Million SEK | -5.34% |
| 2015 Q2 | 11.05 Million SEK | 20.18% |
| 2015 Q1 | 9.19 Million SEK | -8.59% |
| 2015 FY | 42.12 Million SEK | 9.95% |
| 2015 Q4 | 11.41 Million SEK | 9.11% |
| 2014 Q3 | 7.63 Million SEK | -34.41% |
| 2014 Q4 | 10.05 Million SEK | 31.76% |
| 2014 Q2 | 11.64 Million SEK | 29.3% |
| 2014 Q1 | 9 Million SEK | 0.0% |
| 2014 FY | 38.31 Million SEK | 10.11% |
| 2013 FY | 34.79 Million SEK | 3.77% |
| 2012 FY | 33.53 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | 15.539% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 88.562% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 88.562% |
| Arcoma AB | 53.25 Million SEK | -31.405% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -1308.251% |
| BICO Group AB (publ) | 2.84 Billion SEK | 97.543% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | 66.748% |
| CellaVision AB (publ) | 295.99 Million SEK | 76.359% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | -1.517% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -5245.013% |
| C-Rad AB (publ) | 3.8 Million SEK | -1741.474% |
| Duearity AB (publ) | 21.58 Million SEK | -224.188% |
| Dignitana AB (publ) | 74.73 Million SEK | 6.369% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -2491.704% |
| Getinge AB (publ) | 10.75 Billion SEK | 99.35% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -283.881% |
| Iconovo AB (publ) | 63.35 Million SEK | -10.452% |
| Integrum AB (publ) | 90.57 Million SEK | 22.74% |
| Luxbright AB (publ) | 23.09 Million SEK | -203.051% |
| Mentice AB (publ) | 237.06 Million SEK | 70.482% |
| OssDsign AB (publ) | 175.6 Million SEK | 60.151% |
| Paxman AB (publ) | 133.8 Million SEK | 47.701% |
| Promimic AB (publ) | 48.55 Million SEK | -44.126% |
| Qlife Holding AB (publ) | 162.38 Million SEK | 56.907% |
| ScandiDos AB (publ) | 61.03 Million SEK | -14.643% |
| Sectra AB (publ) | 39.06 Million SEK | -79.136% |
| Sedana Medical AB (publ) | 174.52 Million SEK | 59.906% |
| Senzime AB (publ) | 141.51 Million SEK | 50.553% |
| SpectraCure AB (publ) | 12.12 Million SEK | -476.979% |
| Stille AB | 87.21 Million SEK | 19.77% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 98.743% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 84.13% |